TAK-875 – New drug shows promise in diabetes control
An experimental diabetes drug shows promise in lowering blood sugar as much as an older generic medicine with less side effects, a new study has found.
-
-
Recent Posts
-
-
An experimental diabetes drug shows promise in lowering blood sugar as much as an older generic medicine with less side effects, a new study has found.
A structured course teaching the benefits of automated bolus calculator use and flexible intensive insulin therapy improves metabolic control and satisfaction in patients with type 1 diabetes, according to a study published online Feb. 16 in Diabetes Care.
Dr. Topol, a cardiologist and director of Scripps Translational Science Institute in La Jolla, Calif., is already seeing signs of this as companies find ways to hook medical devices to the computing power of smartphones.
Nurses and other health practitioners can now use a smartphone app to help them treat patients with diabetes.
This morning on the last day of the mHealth Summit, Dr. William Maisel, the deputy director and chief scientist of the FDA’s Center for Devices and Radiological Health told attendees that today the FDA had cleared the first iPhone glucose meter.
MCT-Clinical is a software platform that works in conjunction with Allscripts’ electronic health records (EHR) system to transmit not only BG readings but weight, vital signs, caloric intake, and exercise details to a database that clinicians can then analyze and monitor for danger signals.
In an eight-week, placebo-controlled clinical study of 50 overweight individuals with elevated blood glucose levels, test subjects taking GlucAffect lowered their fasting blood glucose by an average of 30%
LifeScan’s OneTouch Verio IQ meter just barely hit market in the U.S., and all meters across the country and across Canada are being “voluntarily removed and replaced” by the company.
Coconut sap has a low Glycemic Index (or GI) informed the Food and Nutrition Research Institute of the Department of Science and Technology
Beta cell functioning also appears to be preserved in some patients years after apparent loss of pancreatic function. The study results appear in the March issue of Diabetes Care.
A team led by Professor Avadesh Surolia, director of National Institute of Immunology, New Delhi, has developed a nanotised insulin for sustained treatment of diabetes. The insulin has passed pre-clinical trials and is ready for clinical trials.
In type 1 diabetes, antibodies attack the insulin-producing cells. Professor Roep has determined exactly which antibodies are involved and works on developing a vaccine.
A team of scientists has uncovered what it considers surprising evidence that insulin resistance, long considered a prime suspect, has little to do with infertility in women with type 2 diabetes.
In 80 percent of diabetic patients treated with this novel drug, blood glucose levels normalized within days – a change that’s not attributed to weight loss.
The A1C test is not affected by stress on the day of the test, nor does it change with any recent changes in the diet, exercise, or medicines. Therefore, it measures your average blood glucose over the previous weeks.
Self-monitoring of blood glucose is of limited use in patients with type 2 diabetes who are not using insulin, finds a new analysis.
About 25 percent of people with diabetes have some level of anemia. This article explains how the two conditions interact.
Johnson & Johnson’s market-leading LifeScan blood glucose monitor will be incorporated intothe remote controller for Insulet’s next-generation OmniPod insulin pump.
ONE in five pregnant women could be diagnosed with gestational diabetes under new criteria doctors say will put more pressure on hospitals already struggling for resources to treat the condition.
The MIT researchers and scientists from MicroCHIPS Inc. reported that they have successfully used such a chip to administer daily doses of an osteoporosis drug normally given by injection.